(37 days)
K 020798
Not Found
No
The description focuses on standard coagulation testing and data management features, with no mention of AI or ML algorithms for analysis or interpretation.
No
The device is described as being for "in vitro Diagnostic Use Only" and performs tests on blood samples to display clotting times. It is not applied to the patient for treatment.
Yes
The device performs "individual point-of-care coagulation tests on fresh or citrated whole blood," and the results "are displayed as clotting times." It is also explicitly stated as "For in vitro Diagnostic Use Only" and intended for "point-of-care coagulation testing." These functions are characteristic of a diagnostic device.
No
The device is described as a "battery operated, hand-held instrument" and a "Whole Blood Microcoagulation System," clearly indicating it includes hardware components beyond just software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The document explicitly states "For in vitro Diagnostic Use Only" multiple times in both the "Intended Use / Indications for Use" and "Device Description" sections.
- Function: The device performs coagulation tests on whole blood, which is a biological sample taken from the body. This is a core characteristic of in vitro diagnostics – testing samples outside of the living organism.
- Purpose: The tests performed (ACT, APTT, PT, INR) are used to assess blood clotting, which is a diagnostic process.
Therefore, based on the provided text, the HEMOCHRON® Signature Elite™ is clearly intended and described as an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The HEMOCHRON® Signature Elite™ Whole Blood Microcoagulation System is a battery-The Hillioon Nort One Ognatan operated, nand-field increment mindude: Activated Clotting Time (ACT+ and ACT-LR), Activated Partial Thromboolastin Time (APTT and APTT Citrate), and Prothrombin Time (PT and PT Citrate). The system is intended to be used with test cuvettes that are available from ITC. For in vitro Diagnostic Use.
Product codes
81JPA
Device Description
The HEMOCHRON® Signature Elite™ Whole Blood Microcoagulation System is a batteryr ne real over to re in the nement that performs individual point-of-care coagulation tests on fresh or operated, norial morantents include: Activated Clotting Time (ACT+ and ACT-LR), Activated Partial Thromboplastin Time (APTT and APTT Citrate), and Prothrombin Time (PT and PT Citrate). The system is intended to be used with test cuvettes that are available from ITC.
Data management capabilities are included with the instrument. These capabilities include Storage of up to 600 patient results and 600 quality control results, designation of quality control levels, tagging of test results with date and time, entry of Patient ID and/or Operator ID or levers, tagging of toot room and bate HEMOCHRON® Configuration Manager software is included with the instrument. This software allows the user to connect a personal computer to the included with the instrument. This octtivation functions using a Microsoft Windows® user interface. HEMOCHRON® ReportMaker" and idms " software which are provided separately, allow the user to connect a personal computer to the instrument and perform various data management and data reporting functions. For in vitro Diagnostic Use. Microsoft and Windows are registered trademarks of Microsoft Corporation.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Laboratory Companson to Fredicate The HEMOCHRON® Signature Elite " and predicate HEMOCHRON® Jr. Signature+ instruments were compared in the laboratory using ITC whole blood control products for each currently Were compared in the HEMOCHRON® Jr. Signature+ instrument (predicate).
Olinical ochipanison to Production to the HEMOCHRON® Signature Elite™ clinical comparison to the predicate HEMOCHRON® Jr. Signature+ instrument system. The evaluation compared results obtained using split patient blood samples on the two instrument systems using each currently 510(k) cleared assay for the HEMOCHRON® Jr. Signature+ instrument system.
A user-based evaluation of the clinical utility and ease of use of the instructional format displayed on the HEMOCHRON® Signature Elite™ instrument system when compared to the predicate HEMOCHRON® Jr. Signature+ instrument system was performed.
All clinical and laboratory data demonstrate the substantial equivalence of the HEMOCHRON® Signature Elite™ instrument system to the predicate HEMOCHRON® Jr. Signature+ instrument system.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K 020798
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 864.5425 Multipurpose system for in vitro coagulation studies.
(a)
Identification. A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays.(b)
Classification. Class II (special controls). A control intended for use with a multipurpose system for in vitro coagulation studies is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
0
FEB 1 0 2005
510(k) Summary
K05 0016
Submitter Information
International Technidyne Corporation 8 Olsen Avenue Edison, NJ 08820 (800) 631-5945
Establishment Registration Number: 2248721
Contact: Leslie Young Date Prepared: 1/3/05
Device Information
HEMOCHRON® Signature Elite™ Whole Blood Microcoagulation System Proprietary Name: Microcoagulation Analyzer Common Name: Multipurpose system for In-Vitro Coagulation (21 CFR 864.5425) Classification Name: Device Class: 11 Hematology & Pathology Panel: 81JPA Product Code:
Predicate Device
Substantial equivalence is claimed to the currently marketed International Technidyne Corporation's HEMOCHRON® Jr. Signature+ Whole Blood Microcoagulation System (K 020798).
Description of Device
The HEMOCHRON® Signature Elite™ Whole Blood Microcoagulation System is a batteryr ne real over to re in the nement that performs individual point-of-care coagulation tests on fresh or operated, norial morantents include: Activated Clotting Time (ACT+ and ACT-LR), Activated Partial Thromboplastin Time (APTT and APTT Citrate), and Prothrombin Time (PT and PT Citrate). The system is intended to be used with test cuvettes that are available from ITC.
Data management capabilities are included with the instrument. These capabilities include Storage of up to 600 patient results and 600 quality control results, designation of quality control levels, tagging of test results with date and time, entry of Patient ID and/or Operator ID or levers, tagging of toot room and bate HEMOCHRON® Configuration Manager software is included with the instrument. This software allows the user to connect a personal computer to the included with the instrument. This octtivation functions using a Microsoft Windows® user interface. HEMOCHRON® ReportMaker" and idms " software which are provided separately, allow the user to connect a personal computer to the instrument and perform various data management and data reporting functions.
For in vitro Diagnostic Use
Microsoft and Windows are registered trademarks of Microsoft Corporation.
1
Intended Use:
The HEMOCHRON® Signature Elite™ Whole Blood Microcoagulation System is a battery-The Hillioon Nort One Ognatan operated, nand-field increment mindude: Activated Clotting Time (ACT+ and ACT-LR), Activated Partial Thromboolastin Time (APTT and APTT Citrate), and Prothrombin Time (PT and PT Citrate). The system is intended to be used with test cuvettes that are available from ITC.
For in vitro Diagnostic Use.
Technological Comparison to Predicate
The HEMOCHRON® Signature Elite™ performs the same assays as the predicate instrument. It rine heation system of the closed in method and clot detection algorithms as the predicate device. The submitted instrument design upgrades the user interface, data storage and data. manipulation functions. The instrument provides a secondary information input pathway using a manipulation farrenoner in addition to manual keypad entry, and offers a larger capacity to store data.
HEMOCHRON® Configuration Manager, which was cleared in the same 510(k) as the predicate device, is a Microsoft Windows® based software application. This software allows the user to configure the instrument to meet specific user needs in the clinical setting. The functionality of configure the instrument to meet specific user nocus in the cannounce of the rature filled in the laterially as the predicate device.
Substantial Equivalence Data Summary
Laboratory Comparison to Predicate
Laboratory Companson to Fredicate
The HEMOCHRON® Signature Elite " and predicate HEMOCHRON® Jr. Signature+ instruments were compared in the laboratory using ITC whole blood control products for each currently Were compared in the HEMOCHRON® Jr. Signature+ instrument (predicate).
Clinical Comparison to Predicate
Olinical ochipanison to Production to the HEMOCHRON® Signature Elite™ clinical comparison to the predicate HEMOCHRON® Jr. Signature+ instrument system. The evaluation compared results obtained using split patient blood samples on the two instrument systems using each currently 510(k) cleared assay for the HEMOCHRON® Jr. Signature+ instrument system.
Clinical User Interface Evaluation
A user-based evaluation of the clinical utility and ease of use of the instructional format displayed on the HEMOCHRON® Signature Elite™ instrument system when compared to the predicate HEMOCHRON® Jr. Signature+ instrument system was performed.
All clinical and laboratory data demonstrate the substantial equivalence of the HEMOCHRON® Signature Elite™ instrument system to the predicate HEMOCHRON® Jr. Signature+ instrument system.
2
Substantial Equivalence Conclusion Summary
The modifications described herein for the HEMOCHRON® Signature Elite™ Whole Blood Microcoagulation System do not alter the intended use, the indications for use, nor the microooaganation tific technology used in the previously cleared predicate device. The HEMOCHRON® Signature Elite " is substantially equivalent to the previously cleared
HEMOCHRON® Signature+" Whole Blood Microcoagulation System (K020798).
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with its wings spread.
FEB 1 0 2005
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Leslie Young Regulatory Affairs Associate International Technidyne Corporation 8 Olsen Avenue Edison, New Jersey 08820
Re: K050016
Trade/Device Name: HEMOCHRON® Signature Elite™ Regulation Number: 21 CFR § 864.5425 Regulation Name: Multipurpose system for In Vitro coagulation studies Regulatory Class: II Product Code: JPA Dated: January 3, 2005 Received: January 4, 2005
Dear Ms. Young:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
4
Page 2 -
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html
Sincerely yours,
Robert Beckerh
Robert L. Becker, Jr., MD, P& Director Division of Immunology and Hematology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
February 3, 2005
International Technidyne Corporation 510(k) Submission International Technidyne Gorporation of othy Crocoagulation System
Indications for Use
510(k) Number (if known): K050016____
Device Name: ________HEMOCHRON® Signature Elite™
Indications for Use:
The HEMOCHRON® Signature Elite™ is a battery operated, hand-held instrument that performs individual point-of-care coagulation tests on fresh or citrated whole blood. The system is intended Incilitiation point coughtton toots of mare coagulation testing. Whole blood test results are displayed as clotting times (in seconds). The HEMOCHRON® Signature Elite™ also displays ulsplayed as clouing times (in socondo). The Hame equivalent values, and the PT INR value.
For in vitro Diagnostic Use Only
Prescription Use XX
(Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRA, Office of In Vitro Diagnostic Devices (OIVD)
Page 1 of 1
Division Sign-Off
O'fice of In Vitro Diagnostic Device
Evaluation ana Salety
Page 4